lectrophysiological testing provides important prognostic information on survivors of out-ofhospital cardiac arrest,'-6 many of whom are at risk for recurrent cardiac arrest and sudden cardiac death.7-13 Patients with persistently inducible ventricular arrhythmia at predischarge electrophysiological study are at significantly higher risk for recurrent cardiac arrest and death in comparison with patients in whom inducible arrhythmias are suppressed with pharmacological and/or surgical therapy.1'13 However, in many of these patients, no effective antiarrhythmic drug regimen can be found.12"14"15 Furthermore, some controversy exists with regard to the prognosis of patients who exhibit no inducible arrhythmia at baseline electrophysiological study.1"'6-2' Among the subgroup of patients with no inducible ventricular arrhythmia and poor left ventricular function, however, there exists a substantial risk of recurrent cardiac arrest.',20,2' Thus, many survivors of out-of-hospital cardiac arrest are suitable candidates for treatment with implantable cardioverter-defibrillators (ICDs). In fact, this therapy is now widely applied in clinical practice and considered by some to be the treatment of choice in cardiac arrest survivors. [22] [23] [24] Pre- vious studies have reported a low incidence of sudden See p 1348 cardiac death in patients with life-threatening ventricular arrhythmias who receive an implantable defibrillator. [25] [26] [27] However, since the introduction of the implantable defibrillator into clinical practice in the early 1980s, no large studies have specifically examined the impact of this new therapy on the long-term outcome of survivors of out-of-hospital cardiac arrest. The objective of this study was to examine the influence of the implantable defibrillator and other variables on long-term outcome in survivors of out-of-hospital cardiac arrest. Methods Electrophysiological studies were performed using a programmable stimulator with constant-current source delivering 2-millisecond rectangular pulses at fivefold diastolic threshold. The protocol for ventricular stimulation included introduction of single and double extrastimuli following pacing drive trains at a minimum of two basic cycle lengths (600 and 400 milliseconds) and at two right ventricular sites in all patients. In the studies before 1982, brief bursts of rapid ventricular pacing (5 to 10 beats at cycle lengths of 400 to 220 milliseconds) were used; however, in all studies since 1982, the protocol included the use of triple extrastimuli during ventricular pacing instead of burst pacing. The end point of the stimulation protocol was the induction of a sustained ventricular arrhythmia, defined as an arrhythmia lasting more than 30 seconds or causing hemodynamic deterioration requiring intervention. Before 1982 and the use of triple ventricular extrastimuli, the reproducible induction of nonsustained ventricular tachycardia was also used as an end point. Ventricular fibrillation was defined as a polymorphous ventricular tachyarrhythmia with a mean cycle length of less than 200 milliseconds.
Electrophysiological testing was performed a median of 2.5 recommended at both institutions in patients who had survived an out-of-hospital cardiac arrest and who continued to have a sustained ventricular arrhythmia inducible at electrophysiological study despite pharmacological and/or surgical therapy. Placement of an implantable defibrillator was also generally recommended for patients who had no inducible sustained ventricular arrhythmias at baseline electrophysiological study and who did not have critical coronary artery disease requiring revascularization or another reversible cause for the cardiac arrest.
Characteristics of Recipients of the Implantable Defibrillator
Implantable defibrillators were placed in 150 patients (45.3%) -89 at Massachusetts General Hospital and 61 patients at the Hospital of the Good Samaritan, Los Angeles. One patient who received an implantable defibrillator and died before hospital discharge is not included in this analysis. One hundred eighty-one patients (54.7%) were treated without implantable defibrillators. Table 1 compares the clinical features of the patients who received an implantable defibrillator with those who were treated without a defibrillator. Patients receiving implantable defibrillators had significantly lower ejection fractions, higher pulmonary capillary wedge pressures, a lower incidence of coronary artery disease and coronary revascularization following the cardiac arrest, a higher incidence of inducible ventricular tachycardia at predischarge electrophysiological study, and a lower incidence of ,B-adrenoreceptor antagonist use than did patients who did not receive a defibrillator. A logrank test and Cox proportional hazards model28 were used to examine the predictors of cardiac mortality, sudden and nonsudden cardiac death, total mortality, and time to defibrillator discharge (excluding spurious shocks). For each of these analyses, patients who did not experience the event of interest were censored at the time of their death or last follow-up. The variables examined are listed in Table 3 , and each was analyzed separately to determine which had a significant effect on each type of failure. All variables were then analyzed using stepwise multiple regression to select the jointly influential predictors (see Table 5 ). The 
Sudden Cardiac Death
The most powerful independent predictor of sudden cardiac death in a multivariate Cox regression model was the absence of the implantable defibrillator (P=.006). The estimated relative risk for sudden cardiac 
Comparison of Outcome of Defibrillator Patients With Nondefibrillator Inducible/Suppressed Patients
In patients with left ventricular ejection fraction of 0.40 or more, the probability of survival free of all-cause mortality for patients without implantable defibrillators whose arrhythmias had been rendered noninducible with pharmacological or surgical therapy was similar to that of patients with implantable defibrillators at 1 and 3 years and poorer than that of defibrillator patients at 5 years (Table 6 ). In patients with poor ventricular function (ejection fraction of less than 0.40) whose arrhythmias were suppressed with drugs or surgical therapy, total mortality was higher at 1 and 5 years and comparable at 3 years to that observed in patients treated with defibrillators (Table 6 ). Patients without defibrillators and with persistently inducible ventricular arrhythmias at hospital discharge experienced higher mortality rates than did defibrillator recipients at all points during the follow-up (Table 6 ). This analysis specifically excludes all patients (n= 103) who had no inducible arrhythmia at baseline electrophysiological study. The powerful independent contribution of the left ventricular ejection fraction to survival in each of these subgroups is evident in Table 6 .
Discussion
In this study of 331 survivors of out-of-hospital cardiac arrest who underwent electrophysiologically guided ther- apy, the only significant independent predictors of both sudden cardiac death and total cardiac mortality were left ventricular ejection fraction of less than 0.40, the presence of inducible ventricular tachycardia at predischarge electrophysiological study, and the absence of an implantable defibrillator (Table 5) . Furthermore, based on the multivariate survival analysis, the presence of more than one of these adverse predictors indicated a multiplicative risk for cardiac mortality. For example, the relative risk for cardiac mortality in a patient with left ventricular ejection fraction of less than 0.40 and no implantable defibrillator was 12.29. Survival analysis showed that the risk of sudden cardiac death was significantly lower in out-of-hospital cardiac arrest survivors receiving implantable defibrillators than in patients without defibrillators, regardless of left ventricular function. Absence of an implantable defibrillator was also an independent predictor of cardiac mortality in this study, although the major difference in total cardiac mortality between patients with and without implantable defibrillators occurred in the subgroup with a left ventricular ejection fraction of less than 0.40.
The absence of an implantable defibrillator was only a marginally significant predictor of total mortality in this study (Table 5 ). This observation is not surprising in that the implantable defibrillator is designed only to terminate life-threatening ventricular arrhythmias and thereby reduce mortality from sudden death. Because ventricular tachycardia and fibrillation are the most common causes of sudden death, it is anticipated that the defibrillator would represent the most powerful determinant of sudden death-free survival (Table 5) . However, sudden deaths comprise only 46% of all cardiac deaths and 34% of total deaths in this study. Thus, to demonstrate a more significant impact of the defibrillator on total mortality, it would be necessary to study a larger patient population. The likelihood of finding such a benefit is suggested by the marked (70 to 80%) reduction in sudden death associated with the defibrillator in this relatively small sample. The impact of the defibrillator on total mortality in this study is further compounded by an overrepresentation in the defibrillator group of patients with poor ventricular function ( Table 1) . Left ventricular ejection fraction, the most powerful independent predictor of cardiac and total mortality, was significantly lower in the defibrillator group than in patients without defibrillators (35.2±16.6% vs 45.3+18.2%). Among the 150 defibrillator recipients, 55 patients (37%) had a left ventricular ejection fraction of 0.40 or more, whereas 111 of 181 patients (61%) without defibrillators had an ejection fraction of 0.40 or more. Despite this bias and the anticipated increase in nonsudden cardiac deaths due to pump dysfunction in defibrillator recipients, a reduction in total mortality was observed in the defibrillator group. These observations are consistent with the findings of a recent retrospective case-control study in which the use of the implantable defibrillator in patients at risk for sudden death was associated with an improved probability of survival.29
In this study, a similar percentage of patients in the defibrillator and nondefibrillator groups had no inducible ventricular arrhythmia at baseline electrophysiology study. Therefore, the improved outcome with defibrillator placement cannot be attributed to an overrepresentation in the defibrillator group of patients with no inducible arrhythmias, who in some studies16,17 have been shown to have a more favorable prognosis. Furthermore, the percentage of patients with ventricular fibrillation as the first rhythm documented at the time of cardiac arrest and with inducible polymorphous ventricular tachycardia or ventricular fibrillation at baseline electrophysiology study was similar in the two patient groups, making overrepresentation of patients with ischemically mediated primary ventricular fibrillation30 among the defibrillator population an unlikely explanation for the enhanced survival in this group. The improved outcome in the defibrillator recipients occurred despite the presence of significantly lower left ventricular ejection fractions, higher pulmonary capillary wedge pressures, a higher incidence of inducible ventricular tachycardia at predischarge electrophysiological study, and a lower incidence of coronary artery revascularization and /3-adrenoceptor antagonist therapy in the defibrillator group. Although the defibrillator group had a lower incidence of coronary artery disease, the incidence of prior myocardial infarction was the same in both populations. While the precise impact of these population differences on outcome cannot be determined in this retrospective analysis, most known predictors of an adverse outcome, except the presence of coronary artery disease,1,13"2031 were biased against the implantable defibrillator group. Surgical mortality was low (one patient, 0.7%) in this study. Defibrillator discharges were predicted by reduced left ventricular ejection fraction, as has also been reported by Levine and colleagues,32 but absence of coronary revascularization was of marginal significance as a predictor of defibrillator discharges in our study. Spurious shocks due to supraventricular arrhythmias, sinus tachycardia, or device malfunction remained a troublesome problem in follow-up care of some of these patients, requiring adjustment of antiarrhythmic drug regimens and causing psychological morbidity. Infection led to removal of the entire ICD system in one patient, seven patients required rehospitalization for lead malfunction, and two patients required pulse generator repositioning. The ICD was removed at the time of cardiac transplantation in three patients and inactivated at the request of two terminally ill patients, both of whom died shortly thereafter.
The morbidity of antiarrhythmic drug therapy is difficult to assess. Nearly a fourth of the patients in the study were taking antiarrhythmic drugs at the time of the presenting cardiac arrest. Because 60% of these patients had inducible ventricular arrhythmias at baseline drug-free electrophysiological study, it is likely that in many cases the cardiac arrest represented a failure of the particular drug rather than a proarrhythmic response.33 However, there is rising concern about the potential for arrhythmogenic effects and increased mortality with class I antiarrhythmic drugs, particularly among patients with left ventricular dysfunction.34 '35 Of the patients treated initially with antiarrhythmic drugs alone, two were successfully resuscitated from a second cardiac arrest and subsequently received an implantable defibrillator. Eleven patients were readmitted to the hospital with symptomatic sustained ventricular tachycardia; six are alive at follow-up (including two patients who received an ICD) and five died predominantly (80%) due to nonsudden cardiac death. Antiarrhythmic drug therapy was frequently used in patients with defibrillators to prevent or control the rate of supraventricular arrhythmias and to reduce the frequency of recurrent ventricular arrhythmias and defibrillator discharges.26,27
Study Limitations
The primary limitations of this study are its retrospective design and the shorter duration of follow-up in the defibrillator group. Because treatment was not randomly allocated, undetected biases may have influenced the selection of patients for ICD and drug therapy and thereby affected the results. However, the two groups of patients were highly comparable in most respects, and those differences that were present and known to influence outcome in this population were, with the exception of the incidence of coronary artery disease, biased against the defibrillator group. The impact of coronary artery disease on outcome in this study is difficult to assess. ICD recipients were less likely than nonrecipients to have coronary artery disease (62% vs 81%), although the incidence of prior myocardial infarction was the same in both groups, and ventricular function was significantly worse in the ICD group (Table 1) . Furthermore, although cardiac mortality was higher in patients with ischemic heart disease versus other diagnoses, the presence of coronary artery disease was not an independent predictor of mortality from any cause in this study (Table 5 ). Nevertheless, it is possible that the lower incidence of coronary artery disease as well as shorter follow-up contributed to a more favorable outcome in the ICD group.
Because the use of implantable defibrillators in this study did not commence until 1983, less information regarding long-term outcome is available in the defibrillator group. Another potential source of bias is the pooling of defibrillator recipients from two institutions. Patients from the Hospital of the Good Samaritan were more likely to be taking antiarrhythmic drugs at the time of the initial cardiac arrest than were ICD recipients from Massachusetts General Hospital. However, no significant differences were detected between the two groups of patients among variables known to predict cardiac and total mortality. Furthermore, the institution of origin was not a predictor of sudden death, nonsudden cardiac death, or total mortality in this study.
Implications for Patient Management
Survivors of out-of-hospital cardiac arrest comprise a heterogeneous patient population in whom an individualized approach must be taken toward diagnosis and management. Treatment should be directed at the underlying structural heart disease, especially advanced ischemic heart disease. In patients with inducible ventricular arrhythmias, attempts to suppress these arrhythmias with antiarrhythmic drugs are appropriate. However, in many patients, no effective antiarrhythmic drug regimen can be defined. In these patients, placement of an implantable defibrillator is supported by the results of this study. The optimal treatment for patients without inducible ventricular arrhythmias is unknown. It is evident that many patients in this group remain at high risk for recurrent cardiac arrest and sudden death. Furthermore, the absence of an inducible arrhythmia at electrophysiological study leaves the physician without an objective end point to guide the selection of pharmacological therapy. A decision regarding defibrillator placement in this patient group must be based on the presence or absence of other treatable factors, most notably, reversible myocardial ischemia, which clearly is causally related to the cardiac arrest in patients with normal or near-normal ventricular function.30,36 At present, patients with an episode of aborted sudden death who manifest no inducible arrhythmia at electrophysiological study and no well-defined reversible cause are appropriate candidates for defibrillator implantation. The fact that this subset of patients receives appropriate defibrillator discharges at a rate comparable to that of other patient groups confirms their ongoing risk for recurrent cardiac arrest.
The limited number of patients and the retrospective design of this study do not permit firm conclusions to be drawn regarding the relative efficacy of suppressive antiarrhythmic drug therapy compared with that of the implantable defibrillator. Nevertheless, in patients with impaired ventricular function, our observations suggest improved survival in the defibrillator group. Furthermore, we observed no significant difference in outcome at 1 and 3 years in patients with well-preserved ventricular function and inducible arrhythmias that were suppressed with pharmacological and/or surgical therapy compared with patients with inducible arrhythmias who were treated with an implantable defibrillator. A trend toward improved survival in the defibrillator group was present at 5 years, however. In this subset of patients, the optimal therapy for achieving long-term survival ultimately must be defined by a prospective trial in which patients with suppressible arrhythmias are randomly assigned to suppressive pharmacological therapy or an implantable defibrillator.
